Opdivo Projected to Grow 38% to 155 Billion Yen, but Ono Chief Sees No Re-Pricing

Ono Pharmaceutical is expecting its PD-1 inhibitor Opdivo (nivolumab) to grow 37.8% to 155 billion yen in the year through March 2023, but President Gyo Sagara says it is unlikely that the drug would be caught by re-pricing rules even...read more